Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Neurobiology of Aging

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.neurobiolaging.2014.07.011PMID 25174649PMCID PMC5289148
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reactive species can be poisonous

  2015cited by this paper
• Enhanced synthesis and release of dopamine in transgenic mice with gain‐of‐function α6* nAChRs

  2014cited by this paper
• Pomegranate juice exacerbates oxidative stress and nigrostriatal degeneration in Parkinson's disease.

  2014cited by this paper
• Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents

  2014cited by this paper
• A Rapid and Sensitive Automated Image‐Based Approach for In Vitro and In Vivo Characterization of Cell Morphology and Quantification of Cell Number and Neurite Architecture

  2014cited by this paper
• Automated imaging system for fast quantitation of neurons, cell morphology and neurite morphometry in vivo and in vitro.

  2013cited by this paper
• Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson's disease.

  2013cited by this paper
• Expression of human E46K-mutated α-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment.

  2013cited by this paper
• Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies

  2013cited by this paper
• Inflammation in Parkinson's disease.

  2012cited by this paper
• High LRRK2 Levels Fail to Induce or Exacerbate Neuronal Alpha-Synucleinopathy in Mouse Brain

  2012cited by this paper
• The role of LRRK2 in inflammatory bowel disease

  2012cited by this paper
• LRRK2 Inhibition Attenuates Microglial Inflammatory Responses

  2012cited by this paper
• LRRK2 kinase activity mediates toxic interactions between genetic mutation and oxidative stress in a Drosophila model: suppression by curcumin.

  2012cited by this paper
• Single-Cell Redox Imaging Demonstrates a Distinctive Response of Dopaminergic Neurons to Oxidative Insults

  2011cited by this paper
• Nitric oxide in neurodegeneration: potential benefits of non-steroidal anti-inflammatories

  2011cited by this paper
• The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease

  2011cited by this paper
• A Rat Model of Progressive Nigral Neurodegeneration Induced by the Parkinson's Disease-Associated G2019S Mutation in LRRK2

  2011cited by this paper
• LRRK2 Controls Synaptic Vesicle Storage and Mobilization within the Recycling Pool

  2011cited by this paper
• Pseudotype-dependent lentiviral transduction of astrocytes or neurons in the rat substantia nigra.

  2011cited by this paper
• Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice.

  2010cited by this paper
• Inhibitors of Leucine Rich Repeat Kinase 2 (LRRK2) Protect Against LRRK2-Models of Parkinson’s Disease

  2010cited by this paper
• Neurotoxic in vivo models of Parkinson's disease recent advances.

  2010cited by this paper
• Enhanced Striatal Dopamine Transmission and Motor Performance with LRRK2 Overexpression in Mice Is Eliminated by Familial Parkinson's Disease Mutation G2019S

  2010cited by this paper
• Leucine‐rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson's disease

  2009cited by this paper
• Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease

  2009cited by this paper
• The Parkinson disease‐associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro

  2009cited by this paper
• A highly reproducible rotenone model of Parkinson's disease.

  2009cited by this paper
• R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice

  2009cited by this paper
• Enhanced function in the good forelimb of hemi-parkinson rats: compensatory adaptation for contralateral postural instability?

  2008cited by this paper
• Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study

  2008cited by this paper
• Localization of LRRK2 to membranous and vesicular structures in mammalian brain

  2006cited by this paper
• Kinase activity of mutant LRRK2 mediates neuronal toxicity

  2006cited by this paper
• Biochemical and pathological characterization of Lrrk2

  2006cited by this paper
• Leucine-rich repeat kinase 2: relevance to Parkinson's disease.

  2006cited by this paper
• A common LRRK2 mutation in idiopathic Parkinson's disease.

  2005cited by this paper
• Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration.

  2005cited by this paper
• Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.

  2004cited by this paper
• Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone.

  2004cited by this paper
• Parkinson's Disease Mechanisms and Models

  2003cited by this paper
• Staging of brain pathology related to sporadic Parkinson's disease.

  2003cited by this paper
• Bag1 is a regulator and marker of neuronal differentiation

  2002cited by this paper
• Forced Limb-Use Effects on the Behavioral and Neurochemical Effects of 6-Hydroxydopamine

  2001cited by this paper
• Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease

  1999cited by this paper
• Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Abeta stabilization.

  1997cited by this paper
• Neuropathology of Parkinson's Disease

  1996cited by this paper
• The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it

  1992cited by this paper
• Measurement of protein using bicinchoninic acid.

  1985cited by this paper
• ReportThe Familial Parkinsonism Gene LRRK 2 Regulates Neurite Process Morphology

  year unknowncited by this paper

• Neurodegeneration models in Parkinson’s disease: cellular and molecular paths to neuron death

  2025cites this paper
• Environmental Factors Exacerbate Parkinsonian Phenotypes in an Asian-Specific Knock-In LRRK2 Risk Variant in Mice

  2025cites this paper
• Behavioral analysis of motor and non-motor impairment in rodent models of Parkinson's disease

  2024cites this paper
• The AAV-α-Synuclein Model of Parkinson’s Disease: An Update

  2024cites this paper
• Modeling Parkinson’s disease in LRRK2 rodents

  2023cites this paper
• The three sisters of fate: Genetics, pathophysiology and outcomes of animal models of neurodegenerative diseases.

  2022cites this paper
• Dopamine Transporter, PhosphoSerine129 α-Synuclein and α-Synuclein Levels in Aged LRRK2 G2019S Knock-In and Knock-Out Mice

  2022cites this paper
• Comprehensive Perspectives on Experimental Models for Parkinson’s Disease

  2021cites this paper
• Current and Emerging MR Methods and Outcome in Rodent Models of Parkinson’s Disease: A Review

  2021cites this paper
• Genetic background influences LRRK2-mediated Rab phosphorylation in the rat brain.

  2021cites this paper
• Clinical Trials In Parkinson's Disease

  2021cites this paper
• Linking the leucine-rich repeat kinase 2 gene, animal models, and Parkinson's disease

  2020cites this paper
• Genetic Models of Parkinson’s

  2020cites this paper
• Pathogenic LRRK2 requires secondary factors to induce cellular toxicity

  2020cites this paper
• The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo.

  2020cites this paper
• Progress in LRRK2-Associated Parkinson’s Disease Animal Models

  2020cites this paper
• The adverse effects of selenomethionine on skeletal muscle, liver, and brain in the steelhead trout (Oncorhynchus mykiss).

  2020cites this paper
• Biological links between traumatic brain injury and Parkinson’s disease

  2020cites this paper
• CAV-2-Mediated GFP and LRRK2G2019S Expression in the Macaca fascicularis Brain

  2020cites this paper
• PhIP exposure in rodents produces neuropathology potentially relevant to Alzheimer's disease.

  2020cites this paper
• Neuromelanin modulates heterocyclic aromatic amine-induced dopaminergic neurotoxicity.

  2019cites this paper
• Genetically engineered animal models of Parkinson's disease: From worm to rodent

  2019cites this paper
• Leucine-rich repeat kinase-2 (LRRK2) modulates paraquat-induced inflammatory sickness and stress phenotype

  2019cites this paper
• Developmental exposure to perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) selectively decreases brain dopamine levels in northern leopard frogs

  2019cites this paper
• Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson’s disease

  2018cites this paper
• Probiotics Affect One‐Carbon Metabolites and Catecholamines in a Genetic Rat Model of Depression

  2018cites this paper
• The impact of murine LRRK2 G2019S transgene overexpression on acute responses to inflammatory challenge.

  2018cites this paper
• LRRK2 exonic variants associated with Parkinson’s disease augment phosphorylation levels for LRRK2-Ser1292 and Rab10-Thr73

  2018cites this paper
• Single Inflammatory Trigger Leads to Neuroinflammation in LRRK2 Rodent Model without Degeneration of Dopaminergic Neurons

  2018cites this paper
• New Developments in Genetic rat models of Parkinson's Disease

  2018cites this paper
• Alterations in the nigrostriatal dopamine system after acute systemic PhIP exposure.

  2018cites this paper
• Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.

  2017cites this paper
• Parkinson disease–associated LRRK2 G2019S transgene disrupts marrow myelopoiesis and peripheral Th17 response

  2017cites this paper
• Mechanisms of Mutant LRRK2 Neurodegeneration.

  2017cites this paper
• Models of LRRK2-Associated Parkinson's Disease.

  2017cites this paper
• Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production

  2017cites this paper
• Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice

  2017cites this paper
• LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function

  2016cites this paper
• The function of orthologues of the human Parkinson's disease gene LRRK2 across species: implications for disease modelling in preclinical research.

  2016cites this paper
• From the Cover: Alterations in Optineurin Expression and Localization in Pre-clinical Parkinson's Disease Models.

  2016cites this paper
• An Update on the Role of Nitric Oxide in the Neurodegenerative Processes of Parkinson's Disease.

  2016cites this paper
• LRRK2 mutations and neurotoxicant susceptibility

  2015cites this paper
• Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.

  2015cites this paper
• Neurodevelopmental Malformations of the Cerebellar Vermis in Genetically Engineered Rats

  2015cites this paper
• Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration*

  2015cites this paper
• The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins.

  2015cites this paper